Tag: Switzerland
Drug Updates

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary Glenmark Specialty S.A. (Switzerland), received FDA approval on its New Drug Application (NDA) for Ryaltris™, an innovative, fixed- dose (metered), prescription, combination drug product nasal spray for the treatment of symptoms of Seasonal Allergic Rhinitis in adults and pediatric patients […]
Digital Health News

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland

WuXi STA – a subsidiary of WuXi AppTec –  today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb (NYSE: BMY). WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding capacity to support its global […]